Focus: Novartis is a global pharmaceutical giant headquartered in Basel, Switzerland, with 78,000 employees and a diversified portfolio across small molecules, vaccines, and biologics. The company commands a major market position across oncology, immunology, neuroscience, cardiovascular, and ophthalmology.
Profile data last refreshed 15h ago · AI intelligence enriched 3w ago
Hot — 1287 jobs added in 30d
Net +528 (1287 new, 759 removed). Aggressive expansion phase.
5 recent layoff filings (12 mo) — 686 affected
Source: state DOL filings via Big Local News
Novartis offers world-class drug development exposure and stable platform diversity, but career security is tempered by ongoing large-scale layoffs and meaningful near-term revenue cliff risk.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Flagship cardiovascular asset dominating 61% of company revenue; protected until 2036.
Help build intelligence for Novartis
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Novartis's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Second-largest patent cliff candidate with $558M Part D spend; loses exclusivity February 2028.
Oncology franchise cornerstone; patent protected until October 2032.
CDK4/6 inhibitor in peak revenue generation; protected until October 2036.
Generic immunomodulator for MS; post-exclusivity asset generating $151M via brand maintenance and formulation advantages.
S1P receptor modulator; immunology franchise contributor with protection until September 2032.
452 discontinued, 226 duplicate formulations not shown
+49 more products with revenue data
Novartis and Eli Lilly sign separate $1.9bn novel drug deals - Life Sciences Intellectual Property Review
Novartis and Eli Lilly sign separate $1.9bn novel drug deals Life Sciences Intellectual Property Review
Antares gets $105M from Novartis for new cancer drugs - BioPharma Dive
Antares gets $105M from Novartis for new cancer drugs BioPharma Dive
Novartis bets on China's growing role in healthcare innovation - 巴士的報
Novartis bets on China's growing role in healthcare innovation 巴士的報
Novartis and Antares target undruggable oncology in $1.8bn deal - European Pharmaceutical Review
Novartis and Antares target undruggable oncology in $1.8bn deal European Pharmaceutical Review
Scorpion team lands $1.9B Novartis deal with new biotech - The Business Journals
Scorpion team lands $1.9B Novartis deal with new biotech The Business Journals
Antares Therapeutics signs potential $1.9 billion cancer drug deal with Novartis - Reuters
Antares Therapeutics signs potential $1.9 billion cancer drug deal with Novartis Reuters
Showing 6 of 10 news items
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Recent peer-reviewed publications with author affiliations at this company
+205 more products
Source: state DOL filings, aggregated via Big Local News
Layoff frequency and scale pose significant job-security risk; employment at Novartis carries elevated restructuring exposure relative to stable Big Pharma peers.
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo